Skip to content

Released Feb 24, 2021, after the close

10-K filed Feb 24, 2021, 55 days after period end · 0001564590-21-008086

Q4 2020 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$15.90Mderived+467.3% vs Q4 2019+110.3% vs Q3 2020
Net Income-$53.11MderivedN/M vs Q4 2019N/M vs Q3 2020
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$33,399,000N/M
Operating Cash Flowderived-$20,664,000N/M
Free Cash Flowderived-$22,936,000N/M
Margins · derived
Operating margin-210.1%+827.6 pt vs Q4 2019
Net margin-334.1%+675.9 pt vs Q4 2019

What the release said

The release

Same quarter

MetricQ4 2020derived from reported figuresQ4 2019Q4 2018Q4 2017
Revenue$15.90M$2.80M$1.66M$1.03M
Net Income-$53.11M-$28.30M-$16.03M-$12.50M
EPS Diluted—-$0.37-$0.25-$0.29

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR